Form 8-K - Current report:
SEC Accession No. 0001193125-23-058235
Filing Date
2023-03-02
Accepted
2023-03-02 16:28:12
Documents
17
Period of Report
2023-03-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d448346d8k.htm   iXBRL 8-K 38219
2 EX-4.2 d448346dex42.htm EX-4.2 396911
3 EX-5.1 d448346dex51.htm EX-5.1 18406
8 GRAPHIC g448346dsp6.jpg GRAPHIC 4304
9 GRAPHIC g448346dsp7.jpg GRAPHIC 3130
  Complete submission text file 0001193125-23-058235.txt   722211

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA amgn-20230302.xsd EX-101.SCH 3870
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20230302_def.xml EX-101.DEF 13250
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20230302_lab.xml EX-101.LAB 21838
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20230302_pre.xml EX-101.PRE 14153
11 EXTRACTED XBRL INSTANCE DOCUMENT d448346d8k_htm.xml XML 5144
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 23699410
SIC: 2836 Biological Products, (No Diagnostic Substances)